High polo-like kinase 1 protein expression is an independent prognostic molecular marker for non-small cell lung cancer. patients

Data suggest that down-regulation of miR-100 could lead to Plk1 over-expression and eventually to docetaxel chemoresistance of lung adenocarcinoma.

Data indicate that polo-like kinase 1 (PLK1) inhibition via mitotic disruption suggeting a potential approach for the treatment of -small cell lung cancer (NSCLC).

Study indicated that miR-296 regulated PLK1 expression and could function as a tumor suppressor in non-small cell lung cancer progression.

Data indicate that polo like kinase 1 (PLK1) is overexpressed in clinical small cell lung cancer (SCLC) tumor samples compared to its expression level in normal lung tissue.

the p53 wild-type cell lines were more sensitive to volasertib treatment, suggesting that p53 might be a predictive biomarker for Plk1 inhibition in non-small-cell lung cancer. Moreover, our results pave the way for new combination strategies with Plk1 inhibitors to enhance antitumor activity.

Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer.

miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells.